nach oben

Endocrine

Erschienen in:

01.02.2015 | Pros and Cons in Endocrine Practice

The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: Cons

verfasst von: Alexander T. Faje, Anne Klibanski

Erschienen in: Endocrine | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Excerpt

The lifetime prevalence of dopamine agonist-treated hyperprolactinemia in women is estimated to be approximately 0.1 %. The incidence peaks in women during early adulthood and declines sharply with advancing age [1]. Women with symptomatic hyperprolactinemia can experience infertility, oligo-amenorrhea, galactorrhea, acne, or hirsutism. These symptoms or the presence of a prolactin-secreting pituitary macroadenoma (>10 mm) or enlarging microprolactinoma are the generally accepted indications for treatment. …

M. Kars, P.C. Souverein, R.M. Herings, J.A. Romijn, J.P. Vandenbroucke, A. de Boer, O.M. Dekkers, Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. J. Clin. Endocrinol. Metab. 94(8), 2729–2734 (2009). doi:10.1210/jc.2009-0177 CrossRefPubMed

D. Seriwatanachai, N. Krishnamra, J.P. van Leeuwen, Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J. Cell. Biochem. 107(4), 677–685 (2009). doi:10.1002/jcb.22161 CrossRefPubMed

A. Klibanski, B.M. Biller, D.I. Rosenthal, D.A. Schoenfeld, V. Saxe, Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J. Clin. Endocrinol. Metab. 67(1), 124–130 (1988). doi:10.1210/jcem-67-1-124 CrossRefPubMed

B. Couzinet, G. Meduri, M.G. Lecce, J. Young, S. Brailly, H. Loosfelt, E. Milgrom, G. Schaison, The postmenopausal ovary is not a major androgen-producing gland. J. Clin. Endocrinol. Metab. 86(10), 5060–5066 (2001). doi:10.1210/jcem.86.10.7900 CrossRefPubMed

H.L. Judd, G.E. Judd, W.E. Lucas, S.S. Yen, Endocrine function of the postmenopausal ovary: concentration of androgens and estrogens in ovarian and peripheral vein blood. J. Clin. Endocrinol. Metab. 39(6), 1020–1024 (1974). doi:10.1210/jcem-39-6-1020 CrossRefPubMed

D.R. Meldrum, B.J. Davidson, I.V. Tataryn, H.L. Judd, Changes in circulating steroids with aging in postmenopausal women. Obstet. Gynecol. 57(5), 624–628 (1981)PubMed

N. Ben-Jonathan, C.R. LaPensee, E.W. LaPensee, What can we learn from rodents about prolactin in humans? Endocr. Rev. 29(1), 1–41 (2008). doi:10.1210/er.2007-0017 CrossRefPubMedCentralPubMed

M.J. Tanner, N.C. Hadlow, R. Wardrop, Variation of female prolactin levels with menopausal status and phase of menstrual cycle. Aust. N. Z. J. Obstet. Gynaecol. 51(4), 321–324 (2011). doi:10.1111/j.1479-828X.2011.01321.x CrossRefPubMed

L. Katznelson, P.N. Riskind, V.C. Saxe, A. Klibanski, Prolactin pulsatile characteristics in postmenopausal women. J. Clin. Endocrinol. Metab. 83(3), 761–764 (1998). doi:10.1210/jcem.83.3.4675 PubMed

10.

N. Kalleinen, P. Polo-Kantola, K. Irjala, T. Porkka-Heiskanen, T. Vahlberg, A. Virkki, O. Polo, 24-hour serum levels of growth hormone, prolactin, and cortisol in pre- and postmenopausal women: the effect of combined estrogen and progestin treatment. J. Clin. Endocrinol. Metab. 93(5), 1655–1661 (2008). doi:10.1210/jc.2007-2677 CrossRefPubMed

11.

S. Karunakaran, R.C. Page, J.A. Wass, The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin. Endocrinol. 54(3), 295–300 (2001)CrossRef

12.

P. Touraine, J.F. Martini, B. Zafrani, J.C. Durand, F. Labaille, C. Malet, A. Nicolas, C. Trivin, M.C. Postel-Vinay, F. Kuttenn, P.A. Kelly, Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J. Clin. Endocrinol. Metab. 83(2), 667–674 (1998). doi:10.1210/jcem.83.2.4564 CrossRefPubMed

13.

B. Corenblum, L. Donovan, The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil. Steril. 59(3), 671–673 (1993)PubMed

14.

G. Testa, W. Vegetti, T. Motta, F. Alagna, D. Bianchedi, C. Carlucci, M. Bianchi, F. Parazzini, P.G. Crosignani, Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 58(2), 69–73 (1998)CrossRefPubMed

15.

U.M. Fahy, P.A. Foster, H.W. Torode, M. Hartog, M.G. Hull, The effect of combined estrogen/progestogen treatment in women with hyperprolactinemic amenorrhea. Gynecol. Endocrinol. 6(3), 183–188 (1992)CrossRefPubMed

16.

C.M. March, O.A. Kletzky, V. Davajan, J. Teal, M. Weiss, M.L. Apuzzo, R.P. Marrs, D.R. Mishell Jr, Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am. J. Obstet. Gynecol. 139(7), 835–844 (1981)PubMed

17.

J. Schlechte, K. Dolan, B. Sherman, F. Chapler, A. Luciano, The natural history of untreated hyperprolactinemia: a prospective analysis. J. Clin. Endocrinol. Metab. 68(2), 412–418 (1989). doi:10.1210/jcem-68-2-412 CrossRefPubMed

18.

M.H. Weiss, J. Teal, P. Gott, R. Wycoff, R. Yadley, M.L. Apuzzo, S.L. Giannotta, O. Kletzky, C. March, Natural history of microprolactinomas: six-year follow-up. Neurosurgery 12(2), 180–183 (1983)CrossRefPubMed

19.

D.A. Sisam, J.P. Sheehan, L.R. Sheeler, The natural history of untreated microprolactinomas. Fertil. Steril. 48(1), 67–71 (1987)PubMed

20.

N. Karavitaki, R. Dobrescu, J.V. Byrne, A.B. Grossman, J.A. Wass, Does hypopituitarism recover when macroprolactinomas are treated with cabergoline? Clin. Endocrinol. 79(2), 217–223 (2013). doi:10.1111/cen.12124 CrossRef

21.

A. Colao, A. Di Sarno, E. Guerra, R. Pivonello, P. Cappabianca, F. Caranci, A. Elefante, L.M. Cavallo, F. Briganti, S. Cirillo, G. Lombardi, Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin. Endocrinol. 67(3), 426–433 (2007). doi:10.1111/j.1365-2265.2007.02905.x CrossRef

22.

J. Kharlip, R. Salvatori, G. Yenokyan, G.S. Wand, Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J. Clin. Endocrinol. Metab. 94(7), 2428–2436 (2009). doi:10.1210/jc.2008-2103 CrossRefPubMedCentralPubMed

23.

O.M. Dekkers, J. Lagro, P. Burman, J.O. Jorgensen, J.A. Romijn, A.M. Pereira, Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 95(1), 43–51 (2010). doi:10.1210/jc.2009-1238 CrossRefPubMed

24.

J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Engl. J. Med. 331(14), 904–909 (1994). doi:10.1056/NEJM199410063311403 CrossRefPubMed

25.

R. Schade, F. Andersohn, S. Suissa, W. Haverkamp, E. Garbe, Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 356(1), 29–38 (2007). doi:10.1056/NEJMoa062222 CrossRefPubMed

26.

E. Valassi, A. Klibanski, B.M. Biller, Clinical review#: potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J. Clin. Endocrinol. Metab. 95(3), 1025–1033 (2010). doi:10.1210/jc.2009-2095 CrossRefPubMed

27.

G. Trifiro, M.M. Mokhles, J.P. Dieleman, E.M. van Soest, K. Verhamme, G. Mazzaglia, R. Herings, C. de Luise, D. Ross, G. Brusselle, A. Colao, W. Haverkamp, R. Schade, G. van Camp, R. Zanettini, M.C. Sturkenboom, Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson’s disease and hyperprolactinaemia: a multi-country, nested case–control study. Drug Saf. 35(2), 159–171 (2012). doi:10.2165/11594940-000000000-00000 CrossRefPubMed

28.

R.S. Auriemma, R. Pivonello, Y. Perone, L.F. Grasso, L. Ferreri, C. Simeoli, D. Iacuaniello, M. Gasperi, A. Colao, Safety of long-term treatment with cabergoline on cardiac valve disease in patients with prolactinomas. Eur. J. Endocrinol. 169(3), 359–366 (2013). doi:10.1530/EJE-13-0231 CrossRefPubMed

29.

S.S. Tworoger, P. Sluss, S.E. Hankinson, Association between plasma prolactin concentrations and risk of breast cancer among predominately premenopausal women. Cancer Res. 66(4), 2476–2482 (2006). doi:10.1158/0008-5472.CAN-05-3369 CrossRefPubMed

30.

S.S. Tworoger, A.H. Eliassen, P. Sluss, S.E. Hankinson, A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer. J. Clin. Oncol. 25(12), 1482–1488 (2007). doi:10.1200/JCO.2006.07.6356 CrossRefPubMed

31.

S.S. Tworoger, A.H. Eliassen, B. Rosner, P. Sluss, S.E. Hankinson, Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res. 64(18), 6814–6819 (2004). doi:10.1158/0008-5472.CAN-04-1870 CrossRefPubMed

32.

S.S. Tworoger, A.H. Eliassen, X. Zhang, J. Qian, P.M. Sluss, B.A. Rosner, S.E. Hankinson, A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res. 73(15), 4810–4819 (2013). doi:10.1158/0008-5472.CAN-13-0665 CrossRefPubMedCentralPubMed

33.

F. Roelfsema, H. Pijl, D.M. Keenan, J.D. Veldhuis, Prolactin secretion in healthy adults is determined by gender, age and body mass index. PLoS One 7(2), e31305 (2012). doi:10.1371/journal.pone.0031305 CrossRefPubMedCentralPubMed

34.

S.E. Hankinson, J.E. Manson, D. Spiegelman, W.C. Willett, C. Longcope, F.E. Speizer, Reproducibility of plasma hormone levels in postmenopausal women over a 2–3-year period. Cancer Epidemiol. Biomarkers Prev. 4(6), 649–654 (1995)PubMed

35.

S.A. Missmer, D. Spiegelman, E.R. Bertone-Johnson, R.L. Barbieri, M.N. Pollak, S.E. Hankinson, Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2- to 3-year period. Cancer Epidemiol. Biomarkers Prev. 15(5), 972–978 (2006). doi:10.1158/1055-9965.EPI-05-0848 CrossRefPubMed

36.

K. Berinder, O. Akre, F. Granath, A.L. Hulting, Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur. J. Endocrinol. 165(2), 209–215 (2011). doi:10.1530/EJE-11-0076 CrossRefPubMed

37.

O.M. Dekkers, J.A. Romijn, A. de Boer, J.P. Vandenbroucke, The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary 13(3), 195–198 (2010). doi:10.1007/s11102-009-0214-y CrossRefPubMedCentralPubMed

38.

J.S. Damiano, K.G. Rendahl, C. Karim, M.G. Embry, M. Ghoddusi, J. Holash, A. Fanidi, T.J. Abrams, J.A. Abraham, Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. Mol. Cancer Ther. 12(3), 295–305 (2013). doi:10.1158/1535-7163.MCT-12-0886 CrossRefPubMed

39.

I. Fernandez, P. Touraine, V. Goffin, Prolactin and human tumourogenesis. J. Neuroendocrinol. 22(7), 771–777 (2010). doi:10.1111/j.1365-2826.2010.02011.x PubMed

40.

S.J. Nyante, J.M. Faupel-Badger, M.E. Sherman, R.M. Pfeiffer, M.M. Gaudet, R.T. Falk, A.A. Andaya, J. Lissowska, L.A. Brinton, B. Peplonska, B.K. Vonderhaar, S. Chanock, M. Garcia-Closas, J.D. Figueroa, Genetic variation in PRL and PRLR, and relationships with serum prolactin levels and breast cancer risk: results from a population-based case–control study in Poland. Breast Cancer Res. 13(2), R42 (2011). doi:10.1186/bcr2864 CrossRefPubMedCentralPubMed

41.

H. Wallaschofski, M. Donne, M. Eigenthaler, B. Hentschel, R. Faber, H. Stepan, M. Koksch, T. Lohmann, PRL as a novel potent cofactor for platelet aggregation. J. Clin. Endocrinol. Metab. 86(12), 5912–5919 (2001). doi:10.1210/jcem.86.12.8085 CrossRefPubMed

42.

A.Q. Reuwer, R. Nieuwland, I. Fernandez, V. Goffin, C.M. van Tiel, M.C. Schaap, R.J. Berckmans, J.J. Kastelein, M.T. Twickler, Prolactin does not affect human platelet aggregation or secretion. Thromb. Haemost. 101(6), 1119–1127 (2009)PubMed

43.

J. Wahlberg, L. Tillmar, B. Ekman, T.L. Lindahl, E. Landberg, Effects of prolactin on platelet activation and blood clotting. Scand. J. Clin. Lab. Invest. 73(3), 221–228 (2013). doi:10.3109/00365513.2013.765963 CrossRefPubMed

44.

S.Y. Mon, A. Alkabbani, A. Hamrahian, J.N. Thorton, L. Kennedy, R. Weil, L. Olansky, K. Doshi, V. Makin, B. Hatipoglu, Risk of thromboembolic events in patients with prolactinomas compared with patients with nonfunctional pituitary adenomas. Pituitary 16(4), 523–527 (2013). doi:10.1007/s11102-012-0450-4 CrossRefPubMed

45.

B. van Zaane, A. Squizzato, A.Q. Reuwer, A.P. van Zanten, M.T. Twickler, O.M. Dekkers, S.C. Cannegieter, H.R. Buller, V.E. Gerdes, D.P. Brandjes, Prolactin and venous thrombosis: indications for a novel risk factor? Arterioscler. Thromb. Vasc. Biol. 31(3), 672–677 (2011). doi:10.1161/ATVBAHA.110.209569 CrossRefPubMed

46.

A. Ciresi, M.C. Amato, V. Guarnotta, F. Lo Castro, C. Giordano, Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Clin. Endocrinol. (2013). doi:10.1111/cen.12204

47.

A.Q. Reuwer, M.T. Twickler, B.A. Hutten, F.W. Molema, N.J. Wareham, G.M. Dallinga-Thie, R.L. Bogorad, V. Goffin, M. Smink-Bol, J.J. Kastelein, S.M. Boekholdt, K.T. Khaw, Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circ. Cardiovasc. Genet. 2(4), 389–395 (2009). doi:10.1161/CIRCGENETICS.109.853572 CrossRefPubMed

48.

S. Shelly, M. Boaz, H. Orbach, Prolactin and autoimmunity. Autoimmun. Rev. 11(6–7), A465–A470 (2012). doi:10.1016/j.autrev.2011.11.009 CrossRefPubMed

49.

N.D. Horseman, K.A. Gregerson, Prolactin actions. J. Mol. Endocrinol. 52(1), R95–R106 (2014). doi:10.1530/JME-13-0220 CrossRefPubMed

50.

S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte, J.A. Wass, S. Endocrine, Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96(2), 273–288 (2011). doi:10.1210/jc.2010-1692 CrossRefPubMed

Titel: The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: Cons
verfasst von: Alexander T. Faje
Anne Klibanski
Publikationsdatum: 01.02.2015
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2015
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-014-0308-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

11.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Im Battle of Experts traten zwei Experten auf dem Diabeteskongress gegeneinander an: Die eine vertrat die Auffassung „Sport statt Spritze“ bei Adipositas und Typ-2-Diabetes, der andere forderte „Spritze statt Sport!“ Am Ende waren sie sich aber einig: Die Kombination aus beidem erzielt die besten Ergebnisse.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

The treatment of hyperprolactinemia in postmenopausal women with prolactin-secreting microadenomas: Cons

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Update Innere Medizin

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Increased low-density lipoprotein cholesterol level is associated with non-vertebral fractures in postmenopausal women

Osteoporosis in patients taking selective serotonin reuptake inhibitors: a focus on fracture outcome

Intraoperative ultrasonography is useful in surgical management of neck metastases in differentiated thyroid cancers

Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy

Optimal use of pegvisomant in acromegaly: are we getting there?

High-normal 2 h glucose is associated with defects of insulin secretion and predispose to diabetes in Chinese adults

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Battle of Experts: Sport vs. Spritze bei Adipositas und Typ-2-Diabetes

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

Vorsicht, erhöhte Blutungsgefahr nach PCI!

Update Innere Medizin